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Abstract
An important paradigm in evolutionary genetics is that of a delicate balance between genetic variants that favorably boost
host control of infection but which may unfavorably increase susceptibility to autoimmune disease. Here, we investigated
whether patients with psoriasis, a common immune-mediated disease of the skin, are enriched for genetic variants that limit
the ability of HIV-1 virus to replicate after infection. We analyzed the HLA class I and class II alleles of 1,727 Caucasian
psoriasis cases and 3,581 controls and found that psoriasis patients are significantly more likely than controls to have gene
variants that are protective against HIV-1 disease. This includes several HLA class I alleles associated with HIV-1 control;
amino acid residues at HLA-B positions 67, 70, and 97 that mediate HIV-1 peptide binding; and the deletion polymorphism
rs67384697 associated with high surface expression of HLA-C. We also found that the compound genotype KIR3DS1 plus
HLA-B Bw4-80I, which respectively encode a natural killer cell activating receptor and its putative ligand, significantly
increased psoriasis susceptibility. This compound genotype has also been associated with delay of progression to AIDS.
Together, our results suggest that genetic variants that contribute to anti-viral immunity may predispose to the
development of psoriasis.
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Introduction
Psoriasis is an immune-mediated, inflammatory skin disease
that is associated with arthritis and other systemic co-morbidities
[1]. Psoriasis is a highly heritable condition, with a monozygotic
twin concordance rate of 70% [2] and an estimated sibling
recurrence risk ls of 4–11 [3]. Linkage studies [4–6] and
genome-wide association studies (GWAS) [7–11] have identified
over 20 psoriasis susceptibilities alleles. However, the locus
consistently displaying the strongest association signal, by many
orders of magnitude, is the major histocompatibility complex
(MHC).
We were intrigued by the observation that several of the most
highly significant SNPs from psoriasis GWAS were identical to the
top SNPs from GWAS of HIV-1 virologic control, a clinical
phenotype whereby certain HIV-1 infected individuals, termed
‘‘HIV-1 controllers,’’ are able to maintain low levels of plasma
HIV-1 RNA in the absence of antiretroviral therapy and who
generally do not develop clinical symptoms [12]. For example,
rs2395029 within the MHC gene HCP5 and a proxy for HLA-
B*57, was identified in a psoriasis GWAS as the SNP with the
largest odds ratio, OR = 4.1, p = 2.13610226 [8]. This same SNP
has been shown to be the first or second most significant SNP in
three GWAS of HIV-1 control [13–15]. The two most significant
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SNPs identified in multiple psoriasis GWAS are rs10484554 and
rs12191877 near HLA-C (r2 = 1 with each other in Europeans) [8–
10]. rs10484554 and rs12191877 were found to be associated with
HIV-1 control [Supplementary Materials in [13,15]] and both are
in moderate linkage disequilibrium (r2 = 0.33) with rs9264942,
another top SNP for HIV-1 control [14–16].
The relationship between psoriasis and HIV-1 is also interesting
because of the clinical observation that HIV-1 infection can
exacerbate existing psoriasis or trigger new-onset psoriasis [17]. As
HIV-1 infection progresses and CD4+ T cell counts decrease,
psoriasis can worsen [18,19]. This has puzzled dermatologists and
infectious disease clinicians because it has been convincingly
established that psoriasis is an immune disorder that is mediated
through activation of T cells. Several explanations for this
‘‘psoriasis HIV-1 paradox’’ have been proposed, including HIV-
1 induced destruction of regulatory CD4+ T cells [20], an increase
in number of memory CD8+ T cells late in disease [21], HIV-1
proteins acting as superantigens [22], or co-stimulation through
traditional antigenic presentation [20].
Due to these genetic and clinical observations, we pursued a
more in-depth analysis of the HLA region in psoriasis to determine
whether patients with psoriasis are enriched for the major genetic
determinants of HIV-1 control. The psoriasis data generated in
this study were compared to the largest GWAS for HIV-1 control
performed to date, involving 516 cases and 1,196 controls and for
which detailed HLA allele information was available [15].
Results
Accurate Imputation of HLA Alleles
We imputed to four-digit resolution the HLA class I alleles (-A, -
B, -C) and HLA class II alleles (-DQA1, -DQB1, -DRB1) of 1,727
psoriasis cases and 3,581 healthy controls which were obtained
from 3 separate case-control cohorts of European ancestry (Table
S1). Imputation was performed using the software HLA*IMP,
which has been shown to have an accuracy of at least 96% for class
I loci and 92% for Class II loci [23]. To further validate the
accuracy of our imputation, we compared the imputed HLA
alleles to empirically obtained HLA class I alleles for a subset of
our samples (n = 98). The concordance was 566/581 alleles
(97.4%), indicating that the imputation was of high accuracy. A
sensitivity analysis examining the imputation accuracy of low
frequency HLA alleles (allele frequency between 1% and 5%)
demonstrated similar high accuracy (177/179 alleles = 98.9%).
Only HLA alleles with a minor allele frequency greater than 1% in
the control group were used for subsequent analyses.
HLA Association Testing Identifies a Similar Genetic
Architecture between Psoriasis and HIV-1 Control
We tested all imputed HLA alleles for association with psoriasis
using logistic regression, adjusting for gender, ancestry, and
cohort. The top ten HLA associations for psoriasis are shown in
Table 1 (Full four-digit and two-digit results in Tables S2 and S3,
respectively). Overall, we observed a striking pattern in which the
HLA alleles which are enriched in psoriasis patients are also
enriched in HIV-1 controllers, and the HLA alleles which have
decreased frequency in psoriasis patients are also decreased in
HIV-1 controllers. We found that psoriasis patients are highly
enriched for HLA-B*57:01 (12.5% in cases vs 3.9% in controls,
p = 5.50610242, OR = 3.61), which in multiple studies has been
shown to be the most significant predictor of both HIV-1 control
and delayed progression time to AIDS [14,15,24–27]. Psoriasis
patients also display a significant enrichment of the HIV-1 control
allele B*13:02, whereas they display a relative paucity of B*07:02,
B*40:01, and C*04:01 which are associated with lack of virologic
control [15]. The HLA allele B*35, almost always seen with
C*04:01, and the most significant HLA allele associated with rapid
progression to AIDS [28,29], was significantly protective against
psoriasis in our dataset (p = 3.2061026, OR = 0.65 [0.54–0.78]).
HLA-B*35 alleles can be segregated into B*35-Px and B*35-PY
alleles, where Px alleles bind peptides with hydrophobic, non-
tyrosine residues at position 9 and PY alleles bind peptides with
tyrosine at position 9. It has been shown that the influence of HLA-
B*35 in accelerating progression to AIDS is mostly attributable to
HLA-B*35-Px alleles [30]. In our psoriasis dataset, the B*35-Px
alleles B*35:02 and B*35:03 together demonstrated a stronger
effect on psoriasis protection (p = 2.961024, OR = 0.47 [0.31–
0.71]) than the B*35-PY allele B*35:01 (p = 5.8661023,
OR = 0.74 [0.60–0.92]).
Stepwise Regression Modeling Identifies HLA Alleles with
Independent Effects on Psoriasis Susceptibility, Including
the HIV-1 Control Alleles B*57:01 and B*27:05
To identify HLA alleles independently associated with psoriasis,
we performed stepwise regression modeling, first conditioning the
association results on the top allele HLA-C*06:02, and then adding
alleles to the model in a stepwise manner. We identified HLA-
C*06:02, B*38:01, A*02:01, B*39:01, B*27:05, B*08:01, B*14:02,
B*55:01, and B*57:01 as HLA class I alleles independently
associated with psoriasis (Table 2). In the multivariate regression
model including all of these alleles, the HIV-1 viral control alleles
B*57:01 and B*27:05 both had significant effect on psoriasis
susceptibility (OR = 1.52 and 1.75, respectively). The contribution
of B*27:05 was more apparent in the regression model than when
B*27:05 was analyzed as a single allele (p = 0.016, OR = 1.32
[1.05–1.66]). The HIV-1 progression allele B*35 remained
independently associated with psoriasis after conditioning on the
top allele C*06:02 (p = 0.0064, OR = 0.77 [0.63–0.93]), but further
conditioning on B*38:01 and A*02:01 resulted in a residual
association signal for B*35 of p = 0.0168, OR = 0.78 [0.64–0.96]).
Author Summary
Individuals with autoimmune disease generally demon-
strate excessive immune system activation, leading to
inflammation and damage of specific target organs.
However, in some cases the detrimental effects of an
overactive immune system might be counterbalanced by a
beneficial effect in protecting against certain infections. In
this study, we investigated whether patients with psoriasis,
a common autoimmune disease of the skin, harbor genetic
variants that are associated with an enhanced ability to
limit replication of the HIV-1 virus. We profiled the HLA
(human leukocyte antigen) immune genes located on
chromosome 6 in 1,727 Caucasian psoriasis cases and
3,581 healthy controls and found that psoriasis patients
are significantly more likely than controls to have gene
variants that are protective against HIV-1 disease. We
found that this enrichment for HIV-1 protective variants
was unique to psoriasis and largely absent in patients with
other autoimmune or inflammatory diseases such as
rheumatoid arthritis, Crohn’s disease, type 1 diabetes, type
2 diabetes, and coronary artery disease. Our results
suggest the possibility that the excessive skin inflamma-
tion in psoriasis may be associated with activation of anti-
viral immune pathways that were important to human
ancestors who encountered viruses similar to HIV-1.
Psoriasis Susceptibility Protects against HIV-1
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We also performed stepwise regression modeling combining
class I and class II HLA alleles. At 4 digit resolution, C*06:02,
B*38:01, DQB1*05:02, DQB1*06:04, and A*02:01 were found to
be independent risk factors; however, at 2 digit resolution, the class
II alleles DQB1*05 and DQB1*06 were no longer significant (data
not shown).
The Extended Haplotype B*57:01–C*06:02–DQA1*02:01–
DQB1*03:03–DRB1*07:01 Is Associated with Both Psoriasis
Susceptibility and HIV-1 Control
We performed haplotype analysis in psoriasis patients and HIV-
1 controllers to help understand how combinations of HLA alleles
contribute to the observed association signals. We estimated the
frequency of HLA haplotypes in our psoriasis case-control cohort
as well as in 214 Caucasian HIV-1 infected individuals (52 HIV-1
controllers, 162 non-controllers) in the SCOPE cohort, whose
HLA class I and II alleles had been previously genotyped. Our
analysis revealed that both psoriasis patients and HIV-1 controllers
are highly enriched for the B*57:01–C*06:02 haplotype as well as
the extended haplotype B*57:01–C*06:02–DQA1*02:01–
DQB1*03:03–DRB1*07:01, thus explaining why these individual
alleles are associated with both phenotypes (Table 3 and Table 4).
We found that the association of DQA1*02:01, DQB1*03:03, and
DRB1*07:01 with psoriasis was nearly completely due to the effects
of C*06:02 or B*57:01, since conditioning DQA1*0201 and
DRB1*0701 on C*06:02 resulted in p = 0.017, OR = 1.21 and
p = 0.199, OR = 1.11, respectively; and conditioning DQB1*0303
on B*57:01 resulted in p = 0.038, OR = 1.33. Thus, the primary
genetic determinants of both psoriasis and HIV-1 control reside
within the class I alleles.
Amino Acids within HLA-B That Are Predictive of HIV-1
Viral Load Are Concordant between HIV-1 Controllers
and Psoriasis Patients
Specific amino acid positions within the peptide binding groove
of HLA class I molecules have been shown to serve as important
mediators for the protective and risk effects of individual HLA
alleles on HIV-1 control [15]. Namely, amino acid residues at
Table 1. Top ten classical HLA alleles associated with psoriasis, and comparison to HIV-1 controllers as published in [15].
Psoriasis HIV
Rank Allele
Frequency in
cases (n =1727)
Frequency in
controls
(n =3581) P-value OR
Frequency in
controllers
(n=516)
Frequency in
non-controllers
(n=1196) P-value OR
1 C*06:02 0.253 0.098 2.91E-77 3.57 0.195 0.081 2.10E-19 2.97
2 B*57:01{ 0.125 0.039 5.50E-42 3.61 0.139 0.032 1.40E-26 5.48
3 DQA1*02:01 0.256 0.152 3.40E-24 1.99 0.184 0.117 1.10E-06 1.67
4 DQB1*03:03 0.118 0.050 1.18E-22 2.69 0.096 0.045 5.40E-09 2.48
5 DRB1*07:01 0.246 0.149 1.98E-20 1.90 0.183 0.117 1.10E-06 1.68
6 B*13:02{ 0.063 0.025 6.20E-17 2.77 0.041 0.019 1.80E-03 2.06
7 A*01:01 0.215 0.165 1.98E-08 1.40 0.139 0.149 NS 1
8 C*04:01{ 0.074 0.120 2.21E-08 0.63 0.058 0.109 5.00E-08 0.42
9 B*07:02{ 0.098 0.122 3.40E-06 0.71 0.061 0.133 1.40E-07 0.45
10 B*40:01{ 0.038 0.052 7.24E-06 0.60 0.029 0.054 8.10E-03 0.55
Alleles marked with { have an independent effect on HIV-1 control. A high degree of similarity is observed between psoriasis and HIV-1 control with respect to the
magnitude and direction of the associated alleles. P values and ORs for psoriasis samples were adjusted by ancestry, gender, and cohort. ORs greater than 1.0
correspond to psoriasis susceptibility and control of HIV-1, whereas ORs less than 1.0 correspond to decreased psoriasis susceptibility and lack of virologic control. NS,
not significant.
doi:10.1371/journal.pgen.1002514.t001
Table 2. HLA class I alleles identified by stepwise logistic regression as independently associated with psoriasis.
Allele Frequency in cases Frequency in controls Stepwise Univariate Multivariate
P value OR P value OR
HLA-C*06:02 0.253 0.098 2.91E-77 3.57 1.03E-45 3.65
HLA-B*38:01 0.035 0.023 2.69E-07 2.21 9.13E-10 2.68
HLA-A*02:01 0.298 0.254 3.68E-05 1.27 2.22E-06 1.32
HLA-B*39:01 0.022 0.012 1.72E-04 2.09 9.17E-06 2.40
HLA-B*27:05 0.049 0.035 1.45E-04 1.62 1.15E-05 1.75
HLA-B*08:01 0.100 0.109 3.01E-04 1.36 1.88E-05 1.45
HLA-B*14:02 0.031 0.030 4.36E-04 1.73 2.34E-04 1.77
HLA-B*55:01 0.023 0.016 4.87E-04 1.84 3.61E-04 1.86
HLA-B*57:01 0.125 0.039 5.77E-04 1.52 5.77E-04 1.52
doi:10.1371/journal.pgen.1002514.t002
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positions 97, 67, and 70 within HLA-B were found to be more
highly associated with HIV-1 control than HLA-B*57:01 and each
of these amino acid positions was found to serve as a strong
predictor of HIV-1 viral load levels in an independent cohort [15].
To determine whether psoriasis is associated with the groups of
alleles that are marked by specific amino acids within HLA
proteins, we used the official protein sequences [31] assigned to
each four-digit HLA allele to perform association testing at each
amino acid position within HLA-A, -B, -C, -DQA1, -DQB1, and -
DRB1. As before, the association testing was adjusted for gender,
ancestry, and cohort. We found that the five most significant
amino acid positions for psoriasis occurred at 3 positions within
HLA-B (residue 97 [p = 1.58610253], residue 67 [p = 4.00
610245], and residue 70 [p = 1.35610240]) and 2 positions with
HLA-C (residue 156 [p = 3.89610251] and residue 97
[p = 4.56610245]) (Table S4). Each of these 5 positions is located
within the peptide-binding groove of the HLA molecule and
directly contacts the bound peptide [32]. At each of these
positions, we investigated whether the direction of the association
signal was consistent between psoriasis patients and HIV-1
controllers. We confirmed that for each position examined, the
amino acid residues associated with psoriasis susceptibility were
associated with HIV-1 virologic control, and the amino acids
associated with a protective effect on psoriasis risk were associated
with HIV-1 progression (Figure 1). For example, alleles marked by
Asn97, Thr97, and Val97 in HLA-B were associated with psoriasis
susceptibility and HIV-1 control while those marked by Arg97 and
Ser97 in HLA-B were associated with psoriasis protection and
HIV-1 progression.
To rule out the possibility that the observed similarities between
psoriasis and HIV-1 control were the result of systematic bias of
the imputation process or general amino acid variability at those
positions, we examined whether these 5 amino acids positions
were associated with other autoimmune or inflammatory diseases.
We examined GWAS data from 5 diseases studied by the
Wellcome Trust Case Control Consortium [33]—rheumatoid
arthritis, Crohn’s disease, type 1 diabetes, type 2 diabetes, and
coronary artery disease—and used the same imputation process as
performed with psoriasis. We found that none of these diseases
displayed the degree of similarity between psoriasis and HIV-1
control when considering the direction and magnitude of the
association signal at these amino acid positions (Figure 1). Crohn’s
disease, which shares some pathophysiological features with
psoriasis [34] and is also slightly enriched for HLA-C*06:02
(p = 4.261025, OR 1.32) and HLA-B*57:01 (p = 3.6861024, OR
1.40), showed some similarity to psoriasis and HIV-1 control at
Table 3. Association testing of HLA B–C haplotypes with psoriasis and HIV-1 control.
Psoriasis HIV
HLA-B HLA-C
Frequency in
cases (n=1727)
Frequency in
controls
(n=3581) P-value OR
Frequency in
controllers
(n =52)
Frequency in
non-controllers
(n=162) P-value OR
57:01 06:02 0.118 0.034 3.06E-65 3.86 0.183 0.046 3.62E-05 4.58
13:02 06:02 0.059 0.024 3.25E-20 2.56 0.029 0.015 NS -
37:01 06:02 0.025 0.013 3.25E-06 1.99 0.019 0.009 NS -
38:01 12:03 0.034 0.022 4.60E-04 1.54 - - NS -
18:01 07:01 0.013 0.022 6.25E-04 0.56 - - NS -
44:03 16:01 0.019 0.029 1.00E-03 0.63 0.010 0.031 NS -
07:02 07:02 0.092 0.112 1.28E-03 0.80 0.087 0.083 NS -
40:01 03:04 0.035 0.048 2.13E-03 0.72 0.019 0.059 NS -
27:05 01:02 0.019 0.012 3.20E-03 1.62 0.067 0.025 NS -
18:01 12:03 0.012 0.019 0.005 0.61 0.010 0.019 NS -
The B*57:01–C*06:02 haplotype is highly enriched in both psoriasis and HIV-1 control patients. The limited sample size of the HIV cohort precludes the detection of
smaller effects. Only haplotypes with p,0.01 are shown.
doi:10.1371/journal.pgen.1002514.t003
Table 4. Association testing of extended class I and II HLA haplotypes with psoriasis and HIV-1 control.
Psoriasis HIV
HLA-B HLA-C
HLA-
DQA1
HLA-
DQB1
HLA-
DRB1
Frequency in
cases
Frequency in
controls P-value OR
Frequency in
cases
Frequency in
controls P-value OR
57:01 06:02 02:01 03:03 07:01 0.088 0.022 1.51E-34 4.30 0.106 0.034 0.0084 3.35
13:02 06:02 02:01 02:02 07:01 0.042 0.015 3.50E-11 2.96 0.010 0.037 NS -
40:01 03:04 03:01 03:02 04:04 0.003 0.013 6.23E-06 0.22 0.028 0.031 NS -
35:01 04:01 01:01 05:01 01:01 0.013 0.026 4.00E-06 0.52 - - - -
40:01 03:04 01:02 06:04 13:02 0.005 0.016 7.60E-04 0.32 - - - -
The B*57:01–C*06:02–DQA1*02:01–DQB1*03:03–DRB1*07:01 haplotype is highly enriched in both psoriasis and HIV-1 control patients. Note: HLA-DQA1 was not
genotyped in the HIV cohort, thus the frequencies reflect HLA B –C–DQB1–DRB1 haplotypes. Only haplotypes with p,0.01 are shown.
doi:10.1371/journal.pgen.1002514.t004
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these positions, but the magnitude of the association was smaller
and several important residues such as Asn70 and Asn97 in HLA-
B and Gln156 in HLA-C were not concordant. Interestingly,
type 1 diabetics showed the opposite effect at many of these
residues (i.e. patients with type 1 diabetes lack HIV-1 control
alleles and have an excess of HIV-1 progression alleles), which
could support the theory that type 1 diabetes is triggered by a
viral infection.
Another important amino acid within HLA-B that may be
relevant for HIV-1 progression is position 116, which not only
interacts with the carboxy-terminal residues of peptides in the F
pocket, but also strongly influences the interaction of HLA class I
molecules with the peptide-loading complex [35,36]. Studies of
HLA-B*44:05 and HLA-B*44:02, which only differ at position 116,
have shown that B*44:05 (containing tyrosine at position 116,
‘‘116Y’’) utilizes a tapasin-independent pathway that leads to a less
optimal peptide repertoire compared to the tapasin-dependent
HLA-B*44:02 (116D) [36]. 116Y is strongly associated with lack of
HIV-1 control, p = 1.6610210, OR = 0.57 [15]. Our data show
that 116Y is strongly associated with decreased susceptibility to
psoriasis, p = 7.96610217, OR = 0.66 [0.60–0.73] (Table S4). In
our dataset, all HLA-B alleles containing 116Y had an odds ratio
less than 1.0, including B*07:02 (p = 3.461026, OR = 0.71),
B*08:01 (p = 0.092, OR = 0.88), B*35:02 (p = 0.038, OR = 0.54),
B*40:01 (p = 7.2461026, OR = 0.60), B*40:02 (p = 0.013,
OR = 0.53), and B*51:01 (p = 0.084, OR = 0.82). Thus, protection
against psoriasis may be associated with presentation of a less-
optimized peptide repertoire.
Together, our data indicate that the genetic similarity between
psoriasis patients and HIV-1 controllers extends to specific
amino acid residues within class I molecules that mediate peptide
binding, influence peptide loading, and which mark viral control
or progression. We additionally performed stepwise regression to
identify amino acid residues that were independently associated
with psoriasis and found Trp156 and Ala24 in HLA-C; Val97,
Leu145, Cys67, and Tyr99 in HLA-B; and Gly107 in HLA-A to be
markers independently associated with psoriasis (Table S5).
Similar to HIV-1 control [15], we found that HLA-B positions
97 and 67 remained in the model, while position 70 dropped out
due to linkage disequilibrium with positions 97 and 67. However,
we caution against an interpretation that the amino acids
identified here as independent are necessarily the functional
ones. Due to the complex LD patterns between the amino acids,
the final output of the stepwise regression model is affected by
the starting variable, and potentially functionally significant
amino acids can be lost because they are tagged by other
residues. For example, HLA-B Gly62, part of the a1 helix located
in the B-pocket of the peptide binding groove, shows strong
independent association with HIV-1 control (p = 4.6610227,
OR = 5.03) [15]. Gly62 is also strongly associated with suscep-
tibility to psoriasis (p = 2.03610239, OR = 3.20) but is in high
LD with HLA-B Val97 and thus drops out of the final psoriasis
model.
The HIV-1 Protective HLA-C 39UTR Deletion
Polymorphism rs67384697 Is Enriched in Psoriasis
Expression levels of HLA-C are modulated by the G/-
polymorphism rs67384697 located within the 39 UTR of HLA-
C, where the presence of the deletion inhibits the binding of the
microRNA hsa-miR-148 to the 39UTR and results in higher
HLA-C surface expression [37]. In a multivariate model of HIV-1
control, the deletion allele of rs67384697 has a strong effect on
viral control independent of the classical alleles HLA-B*57:01 and
HLA-B*27:05, although the high LD of rs67384697 with other
HLA-B and HLA-C alleles makes it difficult to determine whether
rs67384697 (high HLA-C expression) is directly mediating this
effect, or whether the HLA alleles themselves are causal [37].
Nevertheless, rs67384697 has been proposed to be the functional
variant that explains the previously identified protective effect of
rs9264942 on HIV-1 control, where rs9264942 is located -35 kb
upstream of HLA-C and is in moderately high LD with
rs67384697 (r2 = 0.74). We investigated whether rs67384697
was associated with psoriasis by imputing the deletion genotype of
all psoriasis cases and controls. This was made possible by the
near perfect LD between HLA-C four digit classical alleles and
presence or absence of the deletion [Supplementary Table 2 in
[37]]. To confirm the validity of our imputation, we sequenced
the region of the HLA-C 39UTR containing rs67384697 in a
subset of our samples (n = 70) and found a concordance rate of
138/140 alleles (98.6%), indicating the imputation was robust.
Using logistic regression and adjusting for sex, ancestry, and
cohort, we found that deletion allele of rs67384697 was
significantly associated with psoriasis (p = 1.02610229,
OR = 1.72) (Table 5), again confirming the similarity between
psoriasis patients and HIV-1 controllers. We found that the
association of rs67384697 with psoriasis was largely driven by
HLA-C*06:02, since conditioning on HLA-C*06:02 resulted in
only a marginally significant p-value for rs67384697 (p = 0.044,
OR = 1.12). We note, however, that among all HLA-C allotypes,
HLA-C*06:02 shows the highest level of cell surface expression,
which could explain, to some extent, its strong association with
psoriasis.
KIR3DS1 Plus HLA-B Bw4-80I Is a Risk Factor for Psoriasis
Natural killer (NK) cells, a major component of the innate
immune system, respond in the early stages of viral infection by
producing cytokines and killing infected cells. NK-cell responses
are regulated in part by activating and inhibitory killer
immunologlubulin-like receptors (KIRs) on NK cells which engage
HLA class I molecules on target cells. The activating KIR allele
KIR3DS1 on chromosome 19, alone or in combination with its
putative HLA-B ligand Bw4, has been associated with delayed
progression to AIDS and improved HIV-1 outcomes [38–43]. The
HLA-B Bw4 epitope can be identified by the presence of isoleucine
or threonine at amino acid position 80, whereas the Bw6 epitope
contains asparagine at position 80.
Figure 1. Top 5 HLA amino acid positions associated with psoriasis and comparison with HIV-1 control and other autoimmune or
inflammatory diseases. (A) Specific amino acid residues at positions 67, 70, and 97 within HLA-B and positions 97 and 156 within HLA-C are
strongly associated with psoriasis susceptibility or protection, where the strength and direction of association are reflected by the odds ratio at each
residue. All 5 positions occur in the peptide-binding groove of HLA-B or HLA-C. (B) Comparison of odds ratios to HIV-1 control, in which HLA-B
positions 67, 70, and 97 are the top 3 three reported positions [15]. (C–G) Comparison of odds ratios to five other autoimmune or inflammatory
diseases from the Wellcome Trust Case-Control Consortium. None of these demonstrate the same degree of similarity as between psoriasis and HIV-1
control. To demonstrate that this similarity cannot be entirely explained by the association of psoriasis with B*57:01 and C*06:02, we conditioned
each of these residues on both B*57:01 and C*06:02 and found that Cys67, Ser67, Lys70, Asn97, Arg97 in HLA-B remained independently associated with
psoriasis (all p,561024) in the same direction as the association with HIV-1 control. This suggests that the repertoire of peptides bound at HLA-B
may be similar between psoriasis patients and HIV-1 controllers.
doi:10.1371/journal.pgen.1002514.g001
Psoriasis Susceptibility Protects against HIV-1
PLoS Genetics | www.plosgenetics.org 6 February 2012 | Volume 8 | Issue 2 | e1002514
Our HLA data revealed that psoriasis is associated with HLA-B
alleles carrying the Bw4 epitope (p = 1.28610225, OR = 1.66,
Table S4). The association was stronger for Bw4-80I [isoleucine]
(p = 8.28610222, OR = 1.80) than for Bw4-80T [threonine]
(p = 3.4161024, OR = 1.22), which is interesting because Bw4-
80I is thought to have a higher binding affinity for its KIR
receptor than Bw4-80T [44]. We therefore hypothesized that
psoriasis susceptibility might be mediated through activation of
NK cells through KIR3DS1 and its putative partner HLA-B Bw4-
80I. We genotyped KIR3DS1 in a subset of our psoriasis samples
(n = 397) and compared the results to a healthy control cohort with
available KIR3DS1 and HLA genotypes (n = 282). We found that
the presence of the compound genotype KIR3DS1+Bw4-80I was a
strong risk factor for psoriasis (frequency 22.7% in cases vs 6.9% in
controls, p = 1.5461027, OR = 3.92, Table 6). Individuals positive
for KIR3DS1 but lacking Bw4-80I had no increased risk for
psoriasis (p = 0.63, OR = 0.91), and individuals positive for Bw4-
80I but lacking KIR3DS1 had only a borderline increased risk of
psoriasis (p = 0.058, OR = 1.53). To our knowledge, this is the first
report that the compound genotype KIR3DS1+Bw4-80I is a strong
risk factor for psoriasis susceptibility. This finding is again
consistent with our observation that there is significant genetic
similarity between psoriasis patients and HIV-1 controllers;
however, replication of the KIR3DS1+Bw4-80I association in
additional psoriasis cohorts is warranted.
Discussion
In this study, we followed up on the observation that several of
the top SNPs from genome-wide association studies of psoriasis
were identical to the top SNPs from genome wide association
studies of HIV-1 control. Using imputation of HLA alleles, we
found that psoriasis patients are enriched for several of the most
significant known genetic variants associated with HIV-1 control:
HLA-B*57 and HLA-B*27, which are associated with decreased
viral load and increased time to AIDS [14,15,24–27]; specific
amino acid residues at HLA-B positions 97, 67, and 70 that are
strong markers of HIV-1 controller status and viral load [15]; the
deletion SNP rs67384697 which is associated with decreased viral
load independent of HLA-B*57 and HLA-B*27 [37]; and the
activating KIR3DS1 allele in combination with HLA-B Bw4-80I
[42]. Psoriasis patients also demonstrate a significant paucity of
HLA alleles and variants associated with HIV-1 disease progres-
sion [15,28], including HLA-B*35 (especially B*35-Px), B*07:02,
B*40, C*04:01, C*07, and tyrosine 116 in HLA-B associated with
sub-optimal peptide loading (Table S2, Table S4). These effects
were consistent between the 3 psoriasis cohorts examined in this
study, demonstrating that the effects observed were real (Table
S6).
An important question to address, however, is whether the
structural similarity between HLA alleles in psoriasis and HIV-1
control reflects the same underlying causal variants, or merely a
coincidental association due to linkage disequilibrium. Our data
suggest that some, but not all, of the observed similarity can be
attributed to linkage disequilibrium. Our haplotype analysis shows
that both psoriasis patients and HIV-1 controllers are enriched for
the same extended haplotype, B*57:01–C*06:02–DQA1*02:01–
DQB1*03:03–DRB1*07:01. In the HIV-1 controllers, this haplo-
type is likely primarily driven by selection for B*57:01, since
previous studies have shown that the association of C*06:02 with
HIV-1 control is dependent on B*57:01 in Europeans [15] and
B*5801 in Africans [45], although one indirect benefit of C*06:02
for HIV-1 control is its high LD (D9= 1) with the rs67384697
deletion polymorphism. In psoriasis, the haplotype association
appears to be driven more by C*06:02 than B*57:01, since
Table 5. Association of rs67384697 with psoriasis and conditional analysis on HLA-C*06:02 and B*57:01.
Allele Frequency in cases Frequency in controls P value OR 95% CI
rs67384697 del 0.513 0.398 1.02E-29 1.72 1.57-1.89
Condition on C*06:02 0.044 1.12 1.00-1.25
Condition on B*57:01 3.05E-13 1.46 1.32-1.62
rs67384697, a G/del SNP located in the 39UTR of HLA-C, has been shown to modulate HLA-C expression levels by affecting the binding of microRNA hsa-miR-148 to its
target site [37]. rs67384697 is associated with HIV-1 control independent of the classical HLA-alleles HLA-B*5701 and HLA-B*27:05.
doi:10.1371/journal.pgen.1002514.t005
Table 6. Association Testing of KIR3DS1 with Psoriasis.
Genetic variable Frequencya in cases (%) Frequencya in controls (%) P-valueb OR 95% CI
KIR3DS1 without Bw4-80I 79/331(23.9) 63/245(25.7) 6.26E-01 0.91 0.61-1.35
Bw4-80I without KIR3DS1 76/331(23.0) 40/245(16.3) 5.84E-02 1.53 0.98-2.40
KIR3DS1+Bw4-80Ic 75/331(22.7) 17/245(6.9) 1.54E-07 3.92 2.21-7.30
KIR3DS1 185/397(46.6) 92/282(32.6) 2.68E-04 1.80 1.30-2.51
Bw4-80I 154/339(45.4) 58/247(23.4) 3.76E-08 2.71 1.86-3.98
The combination of KIR3DS1 and HLA-B Bw4-80I has a large effect on psoriasis susceptibility, whereas KIR3DS1 without Bw4-80I, and Bw4-80I without KIR3DS1, have
little effect. Thus, the compound genotype KIR3DS1+Bw4-80I drives the individual associations of KIR3DS1 and Bw4-80I with psoriasis (bottom two rows).
aFrequencies of individuals positive for each allele.
bp-values were tested by a two-sided Fisher’s exact test (dominant model).
cLogistic regression based conditional association testing of ‘‘KIR3DS1+Bw4-80I’’ on HLA-C*06:02 remained significant at p = 9.9961025, OR = 3.16 [1.77–5.63], whereas
conditional testing of ‘‘Bw4-80I without KIR3DS1’’ on HLA-C*06:02 resulted in a non-significant p-value of 0.579, OR = 1.14 [0.72–1.80]. Thus, Bw4-80I does not have an
independent effect on psoriasis susceptibility in the absence of KIR3DS1.
doi:10.1371/journal.pgen.1002514.t006
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C*06:02 remains significant after conditioning on B*57:01
(p = 6.86610239, OR = 3.04) and a number of C*06:02 haplotypes
that do not contain B*57:01 still remain associated with psoriasis
(Table 3). In addition, the association of the deletion allele of
rs67384697 with psoriasis appears to be largely driven by LD with
C*06:02. However, it should be noted that variants in high LD
with C*0602 may be contributing to the observed association
signal for C*0602. Interestingly, one can take the association signal
for C*06:02 in psoriasis and perform stepwise conditioning on all
coding amino acids within C*06:02 to demonstrate that the coding
residues do not account for the entire association signal (Table S7).
Therefore, the association of C*06:02 with psoriasis reflects, in
part, other variants in high LD with C*06:02.
Despite the effects of linkage disequilibrium, our data suggest that
some HIV-1 control variants indeed contribute independently to
psoriasis susceptibility. First, both HLA-B*57:01 and HLA-B*27:05
remain associated with psoriasis after conditioning on C*06:02
(B*57:01 p = 1.4361023, OR = 1.45; B*27:05 p = 4.8361024,
OR = 1.52) and both remain independently associated with
psoriasis in our stepwise regression model (Table 2). A previous
analysis of the HLA region in psoriasis by Feng et al. [46] also found
that B*57:01 was independent of C*06:02 in Caucasians; moreover,
in this study B*57:01 was also found to be independent of C*06:02
in a Chinese psoriasis cohort, which is notable because the LD
between C*06:02 and B*57:01 is lower in Asians (D9= 0.41)
compared to Europeans (D9= 0.90) [47]. Prior studies have also
shown that B*27 is a strong risk factor for psoriasis in the subset of
patients with psoriatic arthritis, especially those with axial disease
[48–51]. Second, linkage disequilibrium with C*06:02 does not
explain the lower frequency of the HIV-1 progression allele B*35 in
psoriasis, nor can it account for the concordance of amino acid
residues at HLA-B positions 67, 70, and 97 whose association with
psoriasis was shown to be independent of HLA-B*57:01 and HLA-
C*06:02 (Cys67, Ser67, Lys70, Asn97, Arg97, see Figure 1. legend).
Finally, the provisional association of KIR3DS1+HLA-B Bw4-80I
with psoriasis cannot be due to linkage disequilibrium, because
KIR3DS1 is located on chromosome 19 which segregates indepen-
dently of chromosome 6.
Although B*57:01, B*27:05, and possibly B*35 may have
independent effects in psoriasis, additional studies are needed to
clarify the precise mechanism(s) by which these and other
psoriasis-associated HLA alleles contribute to psoriasis suscepti-
bility or protection. The observation that psoriasis patients and
HIV-1 controllers display concordant amino acids within the
peptide binding groove of HLA-B suggests the possibility that an
unknown psoriasis antigen shares homology with HIV-1 epitopes.
An alternative possibility is that B*57:01, B*27:05, and B*35 do
not restrict antigen presentation in psoriasis, but primarily function
through their ability or inability to activate NK cells. We have
provisionally shown a strong effect of KIR3DS1+Bw4-80I on
psoriasis susceptibility, and B*57:01 contains the Bw4-80I epitope.
The second strongest HLA allele in our stepwise regression model,
B*38:01, also contains the Bw4-80I epitope. B*27:05 contains the
Bw4-80T epitope, while protective alleles B*35 and B*40 contain
the Bw6 epitope, which do not serve as ligands for KIR. Previous
studies have shown that the activating KIR allele KIR2DS1 also
contributes to psoriasis or psoriatic arthritis susceptibility [52–55],
supporting the notion that NK cells may play a role in the
pathogenesis of psoriasis. Finally, we have discussed the potential
role of peptide processing on susceptibility to psoriasis, with the
presence of tyrosine at HLA-B position 116 associated with
protection against psoriasis, where position 116 is located near the
C terminus of the bound peptide. A role for peptide processing
influencing psoriasis risk has been previously identified for the
gene ERAP1, an amino peptidase which regulates the quality of
peptides bound to MHC class I molecules through trimming the
peptide N terminus [10].
The genetic similarity between psoriasis patients and HIV-1
controllers has interesting implications. On a population level, the
data would predict that Caucasian individuals with psoriasis are
more likely than Caucasian individuals without psoriasis to be
HIV-1 controllers, and HIV-1 controllers are more likely than
non-controllers to develop psoriasis. This does not imply that every
individual with psoriasis will be an HIV-1 controller, since only a
fraction of psoriasis patients will harbor, for example, B*57, and
even the presence of B*57 does not guarantee HIV-1 control, as
this allele is present in some HIV-1 progressors. Nevertheless, one
would expect an enrichment of HIV-1 controllers in the psoriasis
population relative to a non-psoriatic population.
Our data also suggest a hypothesis that the existence of psoriasis
may represent aberrant activation of evolutionarily-derived viral
control alleles [56]. Barreiro et al. have shown that several of the
top MHC SNPs associated with both psoriasis and HIV-1 control
reside on haplotypes which show strong evidence of recent positive
selection in the genome, as evidenced by long haplotypes
indicative of rapid expansion of an advantageous allele in the
population [57]. Psoriasis could subsequently result from the
activation of viral control alleles due to the presence of a psoriasis
antigen with sequence homology to HIV-1, or due to other
environmental triggers. Although this study has focused on HLA
and KIR alleles, other non-MHC psoriasis genes are plausibly
associated with host response to viral infection. ERAP1 is involved
in class I peptide processing and demonstrates epistasis with
C*06:02 [10] and IFIH1 encodes a cytoplasmic helicase that
mediates induction of interferon response to viral RNA [10,58].
TNIP1, TNFAIP3, TRAF3IP2, NFKBIA, and REL are associated
with the TNF-a pathway and activation of NF-kB; while IL23R,
IL12B, IL23A, and TYK2 are associated with activation of the
Th17 pathway. Psoriasis is characterized by the upregulation of
the cytokines IFN-a, IFN-c, TNF-a, IL-17, IL-22, and IL-23 [59],
while TNF-a, IFN-c, and Th17+ T cells have been shown to be
important in HIV-1 controllers [60–62].
The enrichment of viral control alleles in psoriasis patients may
also help explain the psoriasis HIV-1 paradox (Figure 2). Psoriasis
patients are more likely to harbor alleles such as HLA-B*57, HLA-
B*27, HLA-C*06 (in high LD with the HLA-C 39UTR deletion
polymorphism), and KIR3DS1+Bw4-80I, theoretically resulting in
vigorous cytotoxic T cell and NK cell responses upon infection
with HIV-1 virus. The pro-inflammatory environment created by
these anti-viral responses, resulting in the production of cytokines
such as TNF-a and IFN-c, would worsen the psoriasis. In
addition, if the psoriasis antigen had sequence homology to HIV-
1, then antigen specific immune responses directed against HIV-1
might cross-react with the psoriasis antigen and also flare the
psoriasis. In either case, reduction of viral load and removal of the
antigenic trigger through treatment with anti-retroviral therapies
would improve the psoriasis, which is indeed seen clinically [17].
This explanatory model is consistent with several observational
studies that patients with severe psoriasis and HIV-1 infection tend
to carry the HLA-C*06 and HLA-B*27 alleles [63,64], because
such alleles would trigger the vigorous immune response associated
with exacerbation of psoriasis.
The data presented here with psoriasis and HIV-1 control
illustrate the delicate balance of the human immune response, in
which processes that safeguard the body against pathogens may
also engage deleterious inflammatory responses. A similar example
occurs with a genetic variant in the SH2B3 gene which may be
protective against bacterial infection but which increases suscep-
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tibility to celiac disease, an autoimmune disease of the gut resulting
from gluten intolerance [65]. Another example can be seen with
the identification of genetic variants in immune function genes that
increase the risk of sepsis, a systemic inflammatory response to
infection which can lead to death [66,67].
In summary, using a large dataset of psoriasis cases and controls,
we have shown that psoriasis patients and HIV-1 controllers share
a high degree of similarity at their HLA loci. While some of this
similarity is attributable to linkage disequilibrium, we present
evidence that much of the similarity may be attributable to shared
biological mechanisms including activation of natural killer cells,
specificity of antigen presentation, and use of optimal MHC class I
peptide processing. The genetic similarity between psoriasis and
HIV-1 control suggests the possibility that psoriasis represents
aberrant activation of pathways associated with anti-viral immu-
nity. If this hypothesis is true, then the study of the biological
pathways active in psoriasis may provide new therapeutic insights
for the treatment of HIV-1.
Materials and Methods
Study Subjects
The study population and source are shown in Table S1. Two
independent genome-wide association scan datasets were used as
cohort 1 and cohort 2 in the present study. All cases and controls
were of European descent. More details on subject characteristics
and recruitment can be found in Liu et al. [8] and Nair et al. [9].
Only the subjects whose HLA alleles were successfully imputed (see
below) were included in our analysis. In cohort 3, 169 psoriasis cases
recruited from Washington University, St. Louis were directly typed
for the class I HLA alleles by combining locus-specific amplification
with hybridization of sequence-specific oligonucleotide probes as
described in [68]; 1,711 control samples of European ancestry were
obtained from studies 66 and 67 of illumina iControlDB. There was
no overlap between the subjects among the three cohorts. Informed
consent was obtained from each participant.
HIV Cohorts
Data generated by this study were primarily compared against a
published genome-wide association study of HIV-1 control
involving 516 HIV controllers of European ancestry (viral load
,2,000 RNA copies/ml by three measurements over at least 12
months without antiviral therapy) and 1,196 controls (treatment-
naı¨ve chronically infected individuals with advanced disease,
median viral load 61,698 copies/ml) [15]. HLA haplotype analysis
was performed on 214 Caucasian HIV-1 infected individuals (52
HIV-1 controllers, 162 non-controllers) from the SCOPE cohort
(Study of the Consequences of the Protease Inhibitor Era), whose
HLA class I and II alleles had been previously directly genotyped.
SCOPE HIV-1 controllers were antiretroviral therapy-naı¨ve
subjects who had at least one year duration of documented
plasma HIV RNA below 2,000 copies/ml, while SCOPE non-
controllers were subjects who had at least one documented viral
load above 10,000 copies/ml.
WTCCC Data
The Wellcome Trust Case-Control Consortium data were
obtained from the WTCCC official website (http://www.wtccc.
org.uk/). In this study, we used Affymetrix 500 K genotyping data
from approximately 2,000 samples from each of five diseases
(rheumatoid arthritis, Crohn’s disease, type 1 diabetes, type 2
diabetes, and coronary artery disease) and 3,000 shared control
samples from the 1958 birth cohort (58C) and the National Blood
Service (NBS). More details about these samples are described
elsewhere [33].
KIR Analysis Cohorts
KIR3DS1 typing was performed on 397 psoriasis subjects from
cohorts 2 and 3 described above. Control HLA and KIR3DS1
data were obtained from 282 healthy Caucasian blood donors
from the Carrington laboratory.
Imputation and Validation of Classical HLA Alleles
The program HLA*IMP [23] was used to impute HLA loci -A,
-B, -C, -DQA1, -DQB1 and -DRB1 to 4-digit resolution in our
genome-wide SNP datasets. Individuals or SNPs with a missing
data frequency above 0.20 were excluded as recommended in the
software manual. A call threshold of 0.7 on the modes of the
posterior HLA type distributions was employed, which represents
a good compromise between accuracy and call rate as suggested
Figure 2. Proposed model of relationship between psoriasis and HIV-1 control. Human ancestors encountered retroviruses similar to HIV-1,
leading to positive selection for viral control alleles such as B*57. Individuals who develop psoriasis are enriched for viral control alleles that are
aberrantly activated by environmental triggers or unknown skin antigens (possibly sharing homology to HIV-1 epitopes). When individuals with
psoriasis become infected with HIV-1, they mount vigorous cytotoxic T cell and natural killer cell immune responses leading to secretion of pro-
inflammatory cytokines which worsens the psoriasis. The genetic determinants for psoriasis and HIV-1 control are overlapping, but not identical.
doi:10.1371/journal.pgen.1002514.g002
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by the author. Imputation accuracy was assessed by comparing the
imputed HLA alleles to directly typed HLA class I alleles in a subset
of our samples (n = 98), comprising 42 samples imputed from
Illumina 300 K SNP data and 56 samples imputed from Perlegen
SNP data. We found that HLA*IMP produces highly accurate HLA
type imputations at HLA class I loci at the 4-digit level. The
concordance for the Illumina 300 K platform was 244/252 alleles
(96.8%) and the concordance for the Perlegen platform was 322/
329 alleles (97.9%), for an overall concordance rate of 566/581
alleles (97.4%). To examine the imputation accuracy of infrequent/
rare HLA alleles, we identified all HLA class I alleles with a
population frequency of less than 5% in individuals of European
descent, according to the online database: http://www.allelefre-
quencies.net. We then examined the accuracy of imputation at the 4
digit level for these infrequent/rare HLA alleles in our subjects for
whom we had both directly genotyped HLA alleles and imputed
HLA alleles. The concordance of HLA alleles with frequency,5%
was 95/102 alleles (93.1%) for the Illumina 300 K platform and
116/122 alleles (95.1%) for the Perlegen platform, for an overall
concordance rate of 211/224 alleles (94.2%). However, our
manuscript excludes HLA alleles with frequency less than 1%.
For HLA alleles with frequency greater than 1% but less than 5%,
the concordance was 78/79 alleles (98.7%) for Illumina 300 K and
99/100 alleles (99.0%) for Perlegen, for an overall concordance rate
of 177/179 alleles (98.9%).
Association Testing and Adjustment for Covariates
Additive logistic regression models in PLINK [69] were used for
most of the association tests, except for the HLA haplotype
association tests. To account for potential population stratification
or admixture in these samples, principal component analyses (PCA)
was performed using the EIGENSTRAT [70]. Seven PCs in cohort
1 and ten PCs in cohort 2 were used for ancestry adjustment, based
on leveling off of the PCA scree plot. The principal component
score for each individual was included as a covariate in all models
along with cohort and gender in logistic regression models.
Multivariate logistic regression was performed in R software
package (http://www.r-project.org/). To examine the consistency
of association signals seen in the 3 cohorts used, a heterogeneity
index was calculated using the meta-analysis module in PLINK.
Stepwise Regression Modeling of Independent HLA
Alleles
Conditional and stepwise logistic regression was performed using
the ‘condition’ function in PLINK to determine whether indepen-
dent effects existed. The method begins with an empty model to
which variables are added in an iterative process as described by
Barcellos et al [71]. Briefly, starting with HLA-C*06:02 which
exhibits the strongest association with psoriasis, we conditioned
candidate HLA alleles on C*06:02 to determine the next most
significant independent effect. For the model including both class I
and class II alleles, the iterative process completes when no
candidate allele demonstrates p,0.0006, which corresponds to the
Bonferroni correction for the 88 HLA candidate alleles with
MAF.1% tested. For the model including only class I alleles, the
iterative process completes when no candidate allele demonstrates
p,0.00096, which corresponds to the Bonferroni correction for the
52 class I candidate alleles with MAF.1% tested.
Association Testing of Amino Acid Positions (Including
WTCCC Diseases)
The amino acid sequence of all HLA alleles is completely
determined by the HLA type at four-digit resolution. We used the
official amino acids sequences defined for known HLA alleles [31]
and our imputed HLA allele data to determine the frequency of
amino acid residues in cases and controls. HLA amino acids
residues were tested for association using a logistic regression
model that corrects for population substructure, gender and cohort
using PLINK. For amino acid positions with .2 alleles, the
omnibus test in the conditional haplotype analysis module in
PLINK was used to determine a single p-value for all alleles at that
position.
Stepwise Regression Modeling of Amino Acid Residues
We performed stepwise logistic regression in PLINK to
determine the amino acid residues that were independently
associated with psoriasis, using the same approach as done with
the HLA alleles. For the amino acid analysis, the algorithm
completes when no remaining candidate residue has p,0.0001,
which corresponds to the Bonferroni correction for the 480 HLA
amino acid residues with MAF.1% tested. For the stepwise
regression modeling of HLA-C 06:02 association signal (Table S7),
the algorithm completes when no candidate residue has p,
0.0006(0.05/87).
Imputation and Validation of rs67384697 Deletion
Polymorphism
Since there is strong linkage disequilibrium between specific
HLA-C alleles and rs67384697 [Supplementary Table 2 in [37]],
we were able to determine the rs67384697 genotype of all
subjects using their HLA-C four digit classical alleles. To ensure
the accuracy of our imputation, we directly sequenced (ABI 3730
DNA analyzer, Quintara Biosciences, Berkeley, CA) the region
of the HLA-C 39UTR containing rs67384697 in a subset of our
samples (n = 70) and determined a high concordance rate of
138/140 alleles (98.6%). The following primers were used for
sequencing of genomic DNA samples: forward 59-gtgagattctggg-
gagctga and reverse 59-gaacagcaactaggcacagg as specified in
[37].
Haplotype Analysis
Arlequin V3.5, based on the EM algorithm, was used to
estimate the frequency of HLA allele haplotypes in our psoriasis
cohorts and the SCOPE HIV cohort. To ensure the accuracy of
haplotype construction, we compared the haplotype frequencies
generated by Arlequin to the frequencies obtained by direct
counting of the phased HLA alleles output from HLA*IMP, and
found the two methods to yield nearly identical results. Haplotype
frequencies were tested for statistically significant differences
between case and control groups using the Chi Square test or
Fisher’s exact test in the R software package.
KIR Genotyping
KIR3DS1 genotyping was performed by using multiplex PCR-
SSP (sequence-specific priming) according to Kulkarni et al with
other minor modifications [72]. Briefly, each reaction contained
15 ng of DNA, 200 mM dNTP, 1.5 mM MgCl2, 0.5 ml 106PCR
buffer, 1 mM of each primer for KIR3DS1 and KIR3DL1 and
0.8 mM of each primer for HLA-DRB1, and 0.025 ml of Platinum
Taq polymerase (Invitrogen, Carlsbad, CA) in a 5 mL final
volume. The polymerase chain reaction (PCR) conditions were:
3 min at 94uC; 5 cycles of 15 s at 94uC, 15 s at 65uC, 30 s at
72uC; 25 cycles of 15 s at 94uC, 15 s at 60uC, 30 s at 72uC; 4
cycles of 15 s at 94uC, 1 min at 55uC, 2 min at 72uC followed by a
final 7 min extension step at 72uC. To confirm the accuracy of the
results, samples were replicated using a second set of KIR3DS1 and
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KIR3DL1 primers from [73]. Phenotype frequencies for the
presence of each gene were estimated by direct counting.
Frequency differences between psoriasis and control groups were
tested for significance by two-sided Fisher’s exact test.
Supporting Information
Table S1 Study population and source. GAIN: The Genetic
Association Information Network. WashU: Washington University
in St. Louis. UCSF: University of California San Francisco.
Illumina iControlDB: an online database of genotype and
phenotype data from individuals that can be used as controls in
association studies.
(DOC)
Table S2 Association results for the imputed classical HLA
alleles at 4-digit resolution. P values and ORs were adjusted for
ancestry, gender, and cohort. The last two columns show the p
values and ORs after conditioning on HLA-C*06:02. Only alleles
with frequency greater than 1% in the control group were
analyzed.
(DOC)
Table S3 Association results for the imputed classical HLA
alleles at 2-digit resolution. P values and ORs were adjusted for
ancestry, gender, and cohort. The last two columns show the p
values and ORs after conditioning on HLA-C*06. Only alleles
with frequency greater than 1% in the control group were
analyzed.
(DOC)
Table S4 Association results for the imputed amino acid residues
in each of the classical HLA loci. P values and ORs were adjusted
for ancestry, gender, and cohort. Only residues with frequency
greater than 1% in the control group were analyzed.
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Table S5 Amino acid residues identified by stepwise logistic
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Table S6 Comparison of p-values and odds ratios (ORs) of the
top HLA alleles, amino acid residues, and HLA-C 39 UTR
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with a consistent direction of association across the 3 cohorts.
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signal on the coding amino acids of HLA-C*06:02. The significant
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